Podcasts about phase ii

We’re starting our read of Lydia Kang’s High Republic novel, Cataclysm. This time, we’re discussing how Phase II characters have been affected by war, tension between the Republic government and the Jedi Order, and why Yaddle > Yoda. For a list of Black-owned bookstores to order from, now and always, click here. You can subscribe […]

Wir statten mal wieder der Hohen Republik einen Besuch ab und sprechen über eine Reihe, die der Okklusionszone einen Besuch abstattet - Inception! In Nachrichten aus der Okklusionszone gehen alle Hauptreihen von Abenteuer bis zur Marvel-Reihe einen kleinen Umweg. Denn alle werden pausiert, während eine Art Brücke in dieser Reihe erzählt werden soll. Diese Brücke hängt aber nicht wirklich zusammen, sondern jeder baut seinen eigenen Pfeiler. Das sorgt am Ende für unterbrochene Hauptreihen, fehlenden Inhalt dort und eine wenig zusammenhängende Minireihe, auf die wir auch hätten verzichten können. Warum einige Aspekte dennoch Spaß machen, nur eben im Kontext einer Minireihe nicht passen, besprechen Ines, Theo und Tobias deshalb in dieser Ausgabe. Es geht um die Frage, welche der Abzweigungen noch am meisten Spaß macht, warum Ines Angst vor Eriadu hat und wieso einer der größten Pluspunkte aus Echos der Angst nun durch anderen Kontext zu einem Kritikpunkt wird. Außerdem könnt ihr auch was gewinnen, wenn ihr in den spoilerfreien Teil reinhört und hier das Formular ausfüllt. Zeitmarken 00:00:00 - Willkommen zu Nachrichten aus der Okklusionszone 00:01:46 - Erwartungen an die Reihe 00:03:49 - Ersteindruck nach dem Lesen 00:05:50 - Was will die Reihe eigentlich erreichen? 00:07:15 - Warum ist hier eine Zeitmarke? 00:08:12 - Welche Story überzeugt am meisten? 00:10:43 - Notwendig für die Hauptreihen? 00:14:10 - Spoiler ab hier: Immer wieder Eriadu (Heft 1) 00:25:25 - Ruu hat keine Ruh (Heft 2) 00:34:33 - Spurensuche Widerwillen (Heft 3) 00:43:40 - Stil stört Handlung (Heft 4) 00:57:08 - Fazit mit den Ninja Turtles 01:00:40 - Was wir uns gewünscht hätten Blick in die Datenbank Zur Werksübersicht von Nachrichten aus der Okklusionszone (Dispatches from the Occlusion Zone) Die Einzelhefte erschienen ab 4. September 2024 bei Dark Horse Ein englischsprachiger Sammelband erschien am 1. Juli 2025 Der deutsche Sonderband bei Panini erschien am 21. Oktober 2025 Die Rezensionen Theo hat die Reihe als Einzelhefte direkt zum englischsprachigen Release rezensiert. Er fand viele lobende Worte für die Reihe, was aber vor allem an der erfreulich wenigen Exposition im Vergleich zu Schatten von Starlight lag. Tobias hat jetzt zum Release des deutschsprachigen Sonderbands seine Rezension geschrieben. Er konnte dem Anspruch und der Umsetzung der Reihe nicht viel abgewinnen, zumal er im direkten Vergleich noch Echos der Angst im Kopf hatte. Das Werk will Brücke sein, ist aber eher ein zwangsweise zu passierender Fährenhafen, um am anderen Ufer mit den eigentlichen Hauptreihen fortzufahren. Den JediCast abonnieren Wir sind auf allen gängigen Podcast-Plattformen vertreten! Abonniert uns also gerne auf Spotify, Apple Podcasts, Google Podcasts (etc.), oder fügt bequem unsere Feeds in euren präferierten Podcast-Player ein. Alle Links dazu findet ihr oben unter dem Player verlinkt sowie auch jederzeit unter dem Audioplayer in der rechten Sidebar. Wir freuen uns auch immer über Bewertungen auf den jeweiligen Podcast-Seiten. Falls ihr umfangreichere Anmerkungen habt, schreibt auch gerne eine Mail an podcast@jedi-bibliothek.de! Unsere Arbeit unterstützen Seit einigen Monaten haben wir nun auch einen Buymeacoffee-Link. Darüber könnt ihr uns einmalig einen gewünschten Geldbetrag zukommen lassen. Damit setzen wir dann Gewinnspiele, Convention-Auftritte (wie demnächst auf der Comic Con in Stuttgart) oder technische Ausstattung für unser Projekt um. Deine Meinung zum Comic Wie hat euch der Sonderband gefallen? Stört euch die Unterbrechung und Auslagerung der Hauptreihen oder ist das genau der Reiz dieses Sonderbandes? Oder fühlt ihr euch auch mehr bei Minireihen wie Echos der Angst zu Hause? Hier geht es zum Gewinnspiel Tragt die Antwort auf die im Podcast gestellte Frage hier unter der Rezension ins Formular ein und gewinnt dank Panini einen von drei Bänden Nachrichten aus der Okklusionszone. Star Wars: Die Hohe Republik ist ein mehrjähriges Buch- und Comicprogramm, das hunderte Jahre vor den Skywalker-Filmen spielt und die Jedi in ihrer Blütezeit zeigt. Weitere Infos, News, Podcasts und Rezensionen gibt es in unserem Portal und in der Datenbank. Beachtet auch unsere Guides zur Lesereihenfolge von Phase I, Phase II und Phase III.

On this week's episode, Israel Policy Forum Policy Advisor and Tel Aviv-based journalist Neri Zilber hosts Dan Shapiro, former U.S. ambassador to Israel. They discuss the method and timing behind the Trump-brokered Gaza ceasefire deal, comparisons with the Biden administration's diplomacy, whether senior U.S. officials are really coming to Israel to "Bibi-sit,” the prospects for Phase I of the deal holding, the challenges looming in Phase II, whether more regional normalization is really at hand, what's next on the Iran front, and more. Support the showFollow us on Instagram, Twitter/X, and Bluesky, and subscribe to our email list here.

This week on the Mark Levin Show, On Monday's Mark Levin Show, 7 million old hippies turned out in the Democrat-Marxist-Islamist No Kings mini-parades on Saturday? Well, 330 million Americans did not. The tea party movements had massive rallies, and it wasn't just one day. How is this President a king? He's working through the courts when he's blocked on improving America. For example, in a victory for America the 9th Circuit court ruled that the National Guard can be deployed in Portland. Also, Democrats turned a continuing resolution into a government shutdown blackmail threat to reverse provisions of the big, beautiful bill. Later, Marxist-Islamist Zohran Mamdani is pro-terrorism - from his associations with Imam Siraj Wahaj, his support for Hamas, his calls to globalize the Intifada, and his ties to the Qatar royal family. If people in NYC vote for Mamdani, they are voting for somebody who embraces terrorists, terrorist organizations, and hence, by implication, terrorism. Mamdani is no moderate, he's a grave threat to the people in New York City. Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Mass legal and illegal immigration without assimilation causes profound cultural and societal changes, leading to a dark period in Western societies where Marxist-Islamist ideology smothers Enlightenment values. You can see this in NYC where foreign-born voters overwhelmingly support socialist-Islamist immigrant candidate Zohran Mamdani in the mayoral race against Andrew Cuomo and Curtis Sliwa. The Democrat Party relies on Marxist-socialist beliefs for power, abandoning the American founding, Declaration, Constitution, separation of powers, and genuine elections, instead favoring unelected judges, bureaucracy, and massive government spending to control the people. Later, Zohran Mamdani got his butt kicked at the NYC debate. He's a sloganeer, which is typical of Marxists, but he won't be substantive at all. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Featuring an interview with Dr Kevin Kalinsky, including the following topics: Prophylaxis, Monitoring and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (0:00) Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;30(9). Abstract  Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract   Clinical Data with Neoadjuvant Datopotamab Deruxtecan from the I-SPY 2.2 Phase II Trial (5:17) Khoury K et al. Datopotamab–deruxtecan in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med 2024;30(12):3728-36. Abstract  Shatsky RA et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 Phase II trial. Nat Med 2024;30(12):3737-47. Abstract  NeoSTAR: A Phase II Study of Response-Guided Neoadjuvant Sacituzumab Govitecan and Pembrolizumab for Localized Triple-Negative Breast Cancer (9:09) Abelman RO et al. A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial. ASCO 2025;Abstract 511.  OptimICE-RD: A Phase III Study Evaluating Sacituzumab Govitecan with Pembrolizumab versus Pembrolizumab with or without Capecitabine for Residual Triple-Negative Breast Cancer (12:56) Tolaney SM et al. OptimICE-RD: Sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncol 2024;20(31):2343-55. Abstract  CME information and select publications

China's major goals for the next five years include achievements in deepening reform and strengthening national security, as the country marches toward socialist modernization (01:15). China continues to share opportunities from its opening up at Phase II of the Canton Fair, and ahead of the China International Import Expo (14:10). Trade delegations from China and the United States will begin talks in Malaysia on Friday (31:38).

On Tuesday's Mark Levin Show, Phase II of the Gaza peace plan is the most challenging due to Hamas, which refuses to disarm or leave Gaza, abuses Palestinians, murders IDF soldiers, and repeatedly violates the ceasefire. Despite warnings from President Trump of potential obliteration, Hamas persists. Qatar's emir, a major Hamas funder and host to its leaders, accuses Israel of genocide and ceasefire breaches while calling for a Palestinian state. Turkey's Erdogan similarly harbors Hamas leaders, threatens Israel, and takes provocative actions. The ceasefire must be enforced urgently to stop ongoing murders and torture, and support should be given to Trump if he orders military action against Hamas. Also, Democrats are keeping the government shutdown by continuing to block a non-controversial continuing resolution to try and blackmail Republicans to approve $1.5 trillion in additional spending. This will generate massive debt—similar to the phony Inflation Reduction Act—leading to inflation, higher prices for gasoline, food, mortgages, and credit cards, ultimately harming average citizens and future generations. Later, Zohran Mandami must be defeated in New York's upcoming mayoral race. He dodges questions on Hamas support; campaigns with Imam Siraj Wahaj, who served as a character witness for the 1993 World Trade Center bombing mastermind and called for jihad. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Featuring a slide presentation and related discussion from Dr Eunice S Wang, including the following topics: All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) not eligible for intensive induction chemotherapy (0:00) Quizartinib-based treatment approaches for FLT3-ITD-mutated and FLT3-ITD wild-type AML (5:21) First- and second-generation IDH inhibitors for AML (17:40) Updated results from the AUGMENT-101 Phase II study of the menin inhibitor revumenib for relapsed/refractory KMT2A-rearranged AML (22:59) Phase Ib/II KOMET-001 study of ziftomenib for relapsed/refractory NMP1-mutant AML (26:42) Novel combination approaches with menin inhibitors for AML (29:11) CME information and select publications

THIS VOYAGE, MARK A. ALTMAN (Pandora, The Librarians, 50 Year Mission), DAREN DOCHTERMAN (associate producer, STAR TREK: THE MOTION PICTURE) & ASHLEY E. MILLER (writer, Thor, X-Men: First Class) welcome the team behind the ill-fated STAR TREK TV series, STAR TREK: PHASE II, to discuss the greatest "What If?" in all Trek history featuring story editor JON POVILL, Vulcan science officer, Xon, DAVID GAUTREAUX and assistant to the producers MICHELE BILLY POVILL as they spill the secrets on another TREK NOT TAKEN. DON'T MISS THE TREKSPERTS AT GALAXYCON ST. LOUIS, MILWAUKEE & COLUMBUS THIS FALL! FOR MORE INFORMATION, GO TO GALAXYCON.COM. **TREKSPERTS+ SUBSCRIBERS NOW GET COMMERCIAL FREE EPISODES ONE WEEK EARLY! SUBSCRIBE TODAY AT TREKSPERTSPLUS.COM****Join us on our new INGLORIOUS TREKSPERTS DISCORD Channel at: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://discord.gg/7kgmJSExeh⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rate and follow us on social media at:Blue Sky: @inglorioustrekspertsTwitter/X:@inglorioustrekFacebook:facebook.com/inglorioustrekspertsInstagram/Threads: @inglorioustrekspertsLearn all that is learnable about Star Trek in Mark A. Altman & Edward Gross' THE FIFTY-YEAR MISSION, available in hardcover, paperback, digital and audio from St. Maritn's Press. Follow Inglorious Treksperts at @inglorioustrek on Twitter, Facebook and at @inglorioustreksperts on Instagram and Blue Sky. And now follow the Treksperts Briefing Room at @trekspertsBR, an entirely separate Twitter & Instagram feed."Mark A. Altman is the world's foremost Trekspert" - Los Angeles Times

Watch The X22 Report On Video No videos found (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:17532056201798502,size:[0, 0],id:"ld-9437-3289"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs");pt> Click On Picture To See Larger Picture China is now in talks again with the US, their plan has failed. Big Antimony refinery is being setup in Alaska, Trump is countering China every step of the way. Bessent warns the longer the shutdown goes it could hurt the economy, this is what the [CB] are trying to do. Investments are pouring into the US. Trump now has the [DS] where he wants them. They called in facist/Hitler and it has failed, he ushered in peace around the world and now when he has peace with Ukraine and Russia they will have a very difficult time pushing these names. The FBI has dismantled the largest human trafficking network. Trump is letting the people know that Phase II of the plan is now on track. Obama is struggling he looks defeated, by the time this is over he will try to escape to Kenya and the D party will cease to exist.   Economy (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:18510697282300316,size:[0, 0],id:"ld-8599-9832"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="https://cdn2.decide.dev/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); https://twitter.com/KobeissiLetter/status/1977907063893225928 New: Alaska Scores Big on Antimony Refinery  Antimony (Sb on the periodic table) is a strategic mineral with many applications. Shooters will recognize it, as it is frequently allied with lead to make a harder, more durable alloy for cast bullets. We should note that lead-antimony alloys have many other uses, from lead-acid batteries to sailboat keels. Antimony is used in other alloys as well, such as antifriction alloys, electric cable sheathing, and type metals for printing presses, which apparently are not completely extinct yet. It's also used in flame retardants, and - this is key - in semiconductors. It's also has applications in pharmaceuticals.  a key strategic mineral. Alaska has antimony. Now, in Alaska, a company called Nova Minerals, with a grant from the War Department, has a contract to build an antimony refinery at Port MacKenzie, west of Anchorage, to process ore from the Estelle gold mine in the West Susitna Mineral District. With Pentagon backing and a goal to begin delivering Alaska-sourced antimony into U.S. supply chains by 2027, Nova Minerals Ltd. has secured a 42.8-acre site at Port MacKenzie west of Anchorage for a refinery that would process antimony concentrates from its Estelle project and other sources."This is a defining moment for Nova Minerals and for U.S. critical mineral independence," Nova Minerals CEO Christopher Gerteisen said upon securing land use permits for the industrial site about four miles from a deepwater port in Southcentral Alaska.The refinery, to be developed by Nova subsidiary Alaska Range Resources (ARR), is part of a strategy to leverage the very high-grade antimony mineralization found on the company's Estelle project about 100 miles west of Port MacKenzie to establish a domestic supply of this metalloid critical to a wide range of military and commercial applications. Antimony is also found in Idaho and Montana. But a majority of antimony production comes from countries that are not particularly friendly to the United States: China, Russia, and Tajikistan, which, between them, account for almost 80 percent of global supply. Source: redstate.com Johnson Warns Current Government Shutdown Could Be Longest Ever House Speaker Mike Johnson (R-La.) said on Oct.

Hot on the heels of CUTISS' $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company's mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of tissue manufacturing with automation and the need for perseverance as a founder and CEO.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the healthcare industry, thanks to the impact of CUTISS, the company she co-founded as a spin-off from the University of Zurich. Here, she and her team have made waves for people suffering from severe skin injuries and defects through regenerative medicine, tissue engineering, and skin pigmentation.

In this episode of STRAT, retired Marine Intelligence Officer Hal Kempfer examines three fast-moving global and domestic developments shaping today's security landscape. First, Hal analyzes the new Gaza peace deal between Israel and Hamas — a fragile, phased agreement that could bring long-awaited hostages home but faces major hurdles in disarmament and governance. Next, he explores the Chicago federal court ruling halting National Guard deployments, unpacking constitutional questions and the broader implications for federal and state authority amid urban unrest. Finally, Kempfer provides a sharp situational update on Ukraine's latest military actions, from deep strikes on Russian refineries to hybrid warfare operations across Europe. As global tensions intensify, Hal connects the dots between these stories to reveal what they mean for U.S. strategy, international stability, and the shifting balance of power worldwide.Takeaways:Israel and Hamas begin Phase I of a U.S.-backed peace deal.Hostage releases and troop withdrawals mark fragile first steps in Gaza.Phase II disarmament and governance talks could easily collapse.Chicago court halts National Guard deployment, citing constitutional concerns.Federal vs. state control of troops faces renewed legal scrutiny.Ukraine expands deep strikes on Russian targets and refineries.Russia's economy and military momentum continue to falter.European nations brace for hybrid warfare and political realignments.#STRATPodcast #HalKempfer #MutualBroadcastingSystem #StrategicRiskAnalysis #GazaPeaceDeal #IsraelHamasCeasefire #NationalGuard #ChicagoRuling #UkraineConflict #RussianEconomy #HybridWarfare #GlobalSecurity #USMilitary #Ceasefire #HostageRelease #InternationalLaw #DefenseAnalysis #Geopolitics #CivilMilitaryRelations #WorldAffairs

When it comes to contraception, most of the innovation in the last century has focused on providing contraceptive alternatives for women. The contraceptive pill was approved by the FDA in 1960, the first IUD approved in 1968, and the female condom in 1993. For men, however, there has been little advancement since the invention of the rubber condom in 1855 and the first vasectomies in humans around the turn of the 20th century.Contraline is a biotechnology company that is aiming to change that record. They are currently heading into Phase II trials with a therapy that they claim is reliable, long lasting, easy to use, and reversible. This week, I talk with Kevin Eisenfrats, CEO of Contraline, about the challenges of bringing a new contraceptive to market, how to manage clinical trials on multiple continents, and what the world might look like if the contraceptive burden passes from women to men.01:21                      Kevin Eisenfrats and Contraline07:28                      Contraline's ADAM09:09                      How ADAM works11:39                      Reversibility is a differentiator for ADAM14:01                      Hormonal gels and contraception17:14                      The phase I trial in Australia21:47                      The implantation process25:07                      Moving into phase II27:04                      The male contraception market29:30                      Fundraising for male contraception33:06                      The gendered burden of contraception34:54                      The future of male contraception36:49                      The cultural and social impact of male contraceptionInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: MedinCell Granted €17M to Develop Cheap Long-Acting ContraceptionInpart Connect: Reversible Male ContraceptiveInpart Connect: Cyclic Peptides as Non-hormonal Male Contraceptive Agents and Methods of Use ThereofInpart Connect: Noninvasive Laser Vasectomy

Send us a textAaron takes the mic solo and unloads on pipeline myths, training excuses, and bad packet habits. Forget the rumor mill—he explains why the Air Force keeps tweaking Special Warfare selection, why “pipeline optimization” isn't a conspiracy, and why faster runners are always the ones who graduate. He drags combat controllers over pistol skills, laughs about swim cap questions, and gives the blunt truth: stop wasting time and train specifically for what actually matters. It's snarky, savage, and brutally useful—classic Aaron, unfiltered.⏱️ Timestamps00:00 – Intro chaos and tech fail shoutout 02:05 – Pipeline rumors: water vs land 04:15 – Why change is constant in selection 08:55 – Pipeline optimization explained (no more wasted time) 11:05 – The real mission: why operators exist 15:40 – Selling the new pipeline in one sentence 17:50 – The Zulu Course: common skills, common pain 19:25 – Combat controller pistol roast 21:40 – What you should actually train for 23:55 – Why fast runners always win 28:40 – Pull-up standards and the Pose Fitness app 33:05 – Grip strength is king 35:20 – Swim efficiency and wall push-offs 39:50 – Stowe Phase I vs Phase II: packet perfection 44:30 – What Phase II really feels like 46:45 – Officers, packets, and dumb mistakes 49:05 – Who actually camps more: PJ, CCT, or SR? 55:35 – Underwaters in OCPs: why it sucks and how to prep 57:55 – Could the Air Force run its own schools? Nope

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Phase I vs. Phase II Metabolism⁠ from the Pharmacology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Small Cap Breaking News You Can't Miss!Here's a quick rundown of the latest updates from standout small-cap companies making big moves today.ESGold (CSE: ESAU; OTCQB: ESAUF)Fully funded to finish construction at the Montauban Gold-Silver Project, with building on track for mid–Q4 2025 and production targeted for 2026. The plan aims to transition from development to cash flow while keeping exploration upside alive in Quebec and a JV opportunity in Colombia. Near-term catalysts include concentrate test results from both projects.Abcourt Mines (TSXV: ABI; OTCQB: ABMBF)At the Flordin Project in Québec, surface work extended gold mineralization 650+ meters west of the Cartwright area and outlined new parallel zones. A standout channel sample hit 9.5 g/t gold over 7.0 m, including 112.7 g/t over 0.5 m. Next up: drill targeting these newly exposed zones. Abcourt will present the update at the Munich Mining Conference, Oct. 3–4, 2025.American Eagle Gold (TSXV: AE)At the NAK copper-gold project (B.C.), the company intersected 73 m of 0.89% copper-equivalent within 277 m of 0.40% from surface—the first high-grade surface result in the North Zone. A new near-surface target inside the central stock also shows strong visible mineralization (assays pending). Three rigs turning, 20+ holes to go, and a cash balance of $36M supported by Teck and South32.Scottie Resources (TSXV: SCOT; OTCQB: SCTSF; FSE: SR80)More strong hits from the Blueberry Contact Zone, including 7.43 g/t gold over 18.75 m and 37.0 g/t over 2.85 m. The 25,000-m drill program is fully funded with

This week Dan Morehead joins the show to discuss the current state of markets & what's next throughout 2025 into 2026. We deep dive into how Dan built conviction in crypto as an asset class back in 2013, does the four year cycle still exist, crypto treasury vehicles, Dan's Solana thesis & more. Enjoy! -- Follow Dan: https://x.com/dan_pantera Follow Jason: https://x.com/JasonYanowitz Follow Empire: https://twitter.com/theempirepod -- Join the Empire Telegram: https://t.me/+CaCYvTOB4Eg1OWJh Start your day with crypto news, analysis and data from David Canellis. Subscribe to the Empire newsletter: https://blockworks.co/newsletter/empire?utm_source=podcasts -- Crypto-native institutions and developers demand institutional-grade infrastructure with regulatory clarity and full asset control. Blockdaemon's Earn Stack is a non-custodial platform combining high-performance staking rewards and seamless DeFi integration with no intermediate smart contract or vaults. Programmatically access leading Ethereum & Solana staking rewards, plus DeFi opportunities across lending protocols, DEXs, and AMMs. Book a Demo! -- Welcome to Get Real — Web3's first-ever campaign rewarding you for creating real-world value. Connect your devices to real-world apps on peaq and earn rewards for: Measuring noise pollution Providing compute Mapping the word And more Total prize pool: 5% of $PEAQ's initial supply. Get Real is relaunching soon — follow peaq on X and get ready. -- Mantle is pioneering ""Blockchain for Banking"" as a revolutionary new category that sits at the intersection of TradFi and web3. Key elements for Mantle as the ""Blockchain for Banking"": - Transactions posted to the blockchain - Compatibility with TradFi rails - Integrated DeFi features Mantle Network, the access layer — transforms Mantle Network into a purpose-built vertical platform — the blockchain for banking — that enables financial services on-chain. Mantle leads the establishment of Blockchain for Banking as the next frontier. Follow Mantle on X (@Mantle_Official) for the latest updates on Mantle as the 'Blockchain for Banking'. -- GEODNET is the world's largest RTK network, delivering real-time, centimeter-level precision for drones, robots, farmers, and first responders. Recognized by the U.S. Congress, this blockchain-powered network supports mission-critical applications across a wide range of industries. Discover how GEODNET is changing the world: [https://geodnet.com] -- Timestamps: (00:00) Introduction (02:44) Buying Bitcoin In The Early Days (07:11) Dan's Macro Outlook In 2025 (17:14) Ads (Blockdaemon, Peaq) (18:44) Does The Four Year Cycle Still Exist? (27:39) Phase II of The Bull Market (29:49) The Crypto IPO Window Is Open (32:44) Ads (Blockdaemon, Peaq) (34:13) Crypto Treasury Vehicles (40:30) The Solana Thesis: Why Pantera Owns $1bn+ Solana (42:45) Are Institutions Still Underallocated To Crypto? (46:33) Ads (Manttle, Goednet) (47:59) Launching Crypto's Longest Running Fund (55:07) Advice For Founders (57:50) Crypto's Biggest Opportunity In The Next 5 Years -- Disclaimer: Nothing said on Empire is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Santiago, Jason, and our guests may hold positions in the companies, funds, or projects discussed.

Ethan is a Baltimore-area investor who moved from offices and strip centers into strictly industrial after years of high capex and constant turnover in those assets. His 30,000 sf small-bay warehouse bought in 2013 for $2.15M has run nearly full for 12 years, needed little capex, and is now worth about $4.5M. Limited new supply of small bay, 3 percent annual rent bumps, and sticky tenants made it a cash cow. He sees big funds drifting down-market from big box to chase yield, but notes small-bay tenants are gritty and practical, so local owners who know the profile often have an edge.He has doubled down on industrial outdoor storage. A 16-acre site near Dover was bought for about $1.2M, improved with gravel, fencing, solar lights, cameras and an app-controlled gate, then run by a truck-parking operator. Pricing is about $175 per spot per month with daily and weekly options, modeled for roughly 180 stalls and now about 65 percent occupied, already covering the mortgage. He financed quickly via a line of credit then plans to refi after stabilization. A failed Phase I led to a clean Phase II, which unlocked the deal. He also owns two 5,000 sf warehouses with 1.5 acre yards leased to a pipe distributor, a contractor and a granite company, plus another IOS site across from Dover being turned into containerized self-storage. Strategy wise he avoids Baltimore City's higher taxes, favors Harford County and secondary markets near highways on the I-95 corridor, and targets IOS parcels of 3 to 5 acres or more where supply is scarce and demand is deep.--

Think you can crack the science first and worry about CMC when you "need it"? That's exactly how promising therapies die in regulatory limbo while patients keep waiting.Your breakthrough discovery means nothing if it's trapped in CMC chaos. While you're perfecting your molecular mechanism, competitors with inferior science but superior CMC strategy are racing past you to IND filing and ultimately, to patients.In this episode, I, David Brühlmann, your usual host, expose the dangerous delusion that's quietly bankrupting biotech startups: the belief that brilliant science automatically translates to successful drug development. Drawing from years of watching founders burn through millions because they treated CMC as an afterthought, I reveal why the smartest scientific minds often make the most catastrophic business decisions.Here's the hard truth you'll confront in this episode:The $50M Misconception: Why "CMC is just manufacturing" thinking destroys companies before they ever reach Phase II. While you're debating molecular targets, smart founders are building systematic CMC advantages that compress timelines and slash costs. The FDA doesn't care how elegant your science is if you can't demonstrate consistent, scalable manufacturing.The Brutal Mathematics of Delay: Systematic CMC approach: 10-12 months to IND, 85% hit timelines. "Figure it out later" approach: 15 months or more, and a much lower success rate. Every month you delay isn't just burning cash. If your therapy could help 10,000 patients annually, that's 833 people per month who don't get treatment because of preventable delays.Three Founder Myths That Kill Programs: The misconceptions about CMC being "basically just manufacturing," bringing in experts "when we need them," and CDMOs handling "the complicated stuff." Each myth leads to the same outcome: brilliant science trapped by business incompetence.Your Four-Action Emergency Protocol: Stop hoping CMC will work out. Start implementing systematic approaches. I give you four specific actions to execute this week, not someday when you're "ready," but right now while you can still prevent the crisis that kills 40% of biotech programs.The competitive reality: While you're listening to this episode, your biggest competitor just moved closer to IND filing. Maybe they completed process validation. Maybe they locked in analytical methods. The question isn't whether CMC matters. It's whether you'll master it before your competitors do.Next step:

We’re concluding our read of Zoraida Cordova’s novel, Convergence, part of Phase II of the High Republic project. This time, we talk about hoarding weapons of mass destruction, trusting your instincts, and real-world pop culture nods in the GFFA. For a list of Black-owned bookstores to order from, now and always, click here. You can […]

We’re continuing our read of Zoraida Cordova’s Convergence, the first adult novel in Phase II of the High Republic project. This time, we talk about life on the ground during wartime, shoddy planetary leadership, and arranged marriage tropes. For a list of Black-owned bookstores to order from, now and always, click here. You can subscribe […]

Oral therapies are projected to account for 25% of the anti-obesity medication market by 2030—but first returns have largely disappointed. This month, shares of both Eli Lilly and Viking Therapeutics took a hit as investors reacted negatively to highly anticipated Phase III and Phase II results for their respective candidates.While the 9.1% placebo-adjusted weight loss generated by Lilly's orforglipron over 72 weeks was an efficacy miss by most analyst accounts, tolerability tripped up oral VK2735's otherwise best-case efficacy scenario—10.9% weight loss after just 13 weeks. These murky results have left observers wondering, just how game-changing these pills will be and which ones will be most effective?In such a hot space, Lilly's and Viking's results—which follow Novo Nordisk's new drug application for an oral form of Wegovy in May—are only the tip of the iceberg. Stay tuned to BioSpace for further in-depth coverage of the space as we learn which investigational assets will make it across the regulatory finish line and which will join the weight-loss wasteland.

Collective Mining continues to define the shallow portion of the Apollo system with new drill results. Torq Resources and its Phase II drilling has discovered a new copper-gold porphyry area. GoldMining shares results of historic drill core re-assayed for antimony. Q2 Metals share positive met test work from Cisco. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

Amapiano and 3Step grooves for the real late night lifers.

We’re reading Quest for the Hidden City, a High Republic middle-grade novel by George Mann. Join us as we discuss horror in Star Wars, Phase II worldbuilding, and the importance of a good copyeditor. For a list of Black-owned bookstores to order from, now and always, click here. You can subscribe to Audible and purchase […]

We’re discussing the second half of Path of Deceit, a YA novel by Tessa Gratton and Justina Ireland, and the first book in Phase II of The High Republic Project. Join us as we talk about the origins of the Nihil, the GFFA’s onsistently short memory, and an ending that absolutely blindsided us (in a […]

Dr Murali Ramachandra, CEO of Aurigene Oncology, talks to Anju Ghangurde about the tough biotech funding environment, promising pipeline assets including a CAR-T cell therapy in Phase II and ‘hybrid' manufacturing options, besides outcome-based reimbursement models. The promise of bispecifics and multispecifics in oncology, including Chinese biotech Akeso's PD-1/VEGF bispecific antibody, are some of the other topics he discussed.

Laurie Adami seemed to have it all.  She was the president of her company, at age 40, she had just had a son and still found time to lead an active lifestyle.  However, in 2003, her health took a turn for the worse.  She felt a lump in her abdomen, experienced frequent, lengthy sinus infections and chronic fatigue.  All this led to a diagnosis of Stage IV Follicular Non-Hodgkin Lymphoma.  After six unsuccessful treatment regimens, she achieved complete remission on the seventh try, completing a battle that ran twelve years.   When Laurie initially brought her symptoms to the attention of her family doctor, they were dismissed as, at worst, a hernia, and exhaustion due to her demanding schedule; but Laurie insisted there was nothing ordinary about her symptoms and changed doctors.   She saw a hernia specialist who ordered a CT scan, which revealed a mass the size of a small watermelon on her abdomen.  After a biopsy, Laurie learned she had Stage IV Follicular Non-Hodgkin Lymphoma.  At that time, she had no idea of the difficulty and length of the journey awaiting her.   The first of six treatments that failed to overcome her diagnosis was in 2006 and called R-CHOP.  It was a mix of Rituxan plus Cytoxan, Adriamyacin and Prednisone.   Next in 2008 was a clinical trial of Rituxan, along with an HDAC inhibitor.   In 2010, Laurie tried Bendamustin, a medication popular in Eastern Europe.   When that didn't work, later in the year, she went with Bexxar Radioimmunotherapy.   Of the first six regimens, Laurie had the most success with a pi3 kinase inhibitor called Zydelig.  For five and a half years ending in 2016, it shrunk the tumor without eliminating it. The tumor returned and for six months ending in September 2017, she tried infusions of Gazvya.   On July 16, 2018, her tumor was still around, but Laurie qualified for a Phase II clinical trial of Yescarta CAR-T therapy.  Some 29 days later, her lymphoma specialist informed her she was in full remission.   Laurie Adami has resumed an active lifestyle, and does plenty of traveling, most of it to public speaking engagements, as she serves as an advocate for the Leukemia & Lymphoma Society.   Additional Resources:   Support Group:   The Leukemia & Lymphoma Society  https://www.lls.org  

In this episode, we’re starting Phase II of the High Republic with Path of Deceit, a YA novel by Tessa Gratton and Justina Ireland. Join us as we discuss the state of the galaxy 400 years before the start of the Skywalker Saga, early connections to Phase I, and a new Force cult, the Path […]

Cam Coley returns to the show for his first update. After briefly reminding listeners of Cam's falconry situation, he and I talk about the progress that he has made with his new English setter pup.  Cam then tells us which one of the two options he was considering when we last spoke - going strait to flying wild quarry or opting to transition to Phase II of the Perfect Pigeon approach. We then discuss the use of bagged quarry in South African falconry. Cam had indicated that it was his intent to release his peregrine at the end of August and I ask Cam if he intends to follow through with that plan, and why he believes that doing so is in the best interests of the hawk. If, in fact, Cam does release his falcon, then it was his intent to replace it with either a passage lanneret or a musket black spar - he tells us which of the two options he has settled on. We then focus on some highlights of his season thus far. We conclude the episode with a description of Cam's most recent flight.  Thanks for listening to the Fat Bird, Ugly Dog Podcast - I hope you enjoy the episode.

Erik Wetterling, Founder and Editor of The Hedgeless Horseman website, joins us to review the value proposition that has his attention in the 3 pre-discovery gold and copper exploration companies, that have large Tier 1 drill targets and the potential for rapid upside moves if they make a compelling discovery and hit with the drill bit on current programs.     >> The companies we discussed in the interview are:   Rackla Metals Inc. (TSX-V: RAK) (OTC: RMETF) – On July 14th, 2025 Rackla Metals announced that drilling and had commenced at the BiTe zone on the Grad property NWT.  The Grad property was staked in July of 2024, and immediate prospecting defined strong gold mineralization at the base of the south facing cliff.  Further sampling in August identified significant sheeted veining hosted in the intrusive and that combined with the gold, bismuth and tellurium geochemistry made it clear that the Company had discovered a compelling Reduced Intrusion-related Gold Systems (RIRGS) occurrence that had never previously been identified or staked.   Inflection Resources Ltd. (CSE: AUCU) (OTCQB: AUCUF) – On July 21, 2025, Inflection Resources announced that it completed the acquisition of an 100% interest in a portfolio of copper-gold projects in the Northern Territory and New South Wales, Australia from subsidiaries of Newmont Corporation. This provides the company optionality on how to advance those properties. The main near-term value drivers will be when more assays get released from any of their four projects that JV option partner AngloGold Ashanti elected to advance to Phase II earn-in. The four Designated Projects are Duck Creek, Trangie, Crooked Creek and Nyngan.   Westward Gold Inc. (CSE: WG) (OTCQB: WGLIF) - On July 8, 2025, Westward Gold announced that drilling is underway at its flagship Toiyabe Hills Property in Lander County, Nevada. Over the next several months, Westward will be testing its Campfire Target Complex for the first time, with approximately 5,000 metres (~16,500 feet) of reverse-circulation (“RC”) drilling across this top-priority zone within the ~61 square-kilometer consolidated Property.     * In full disclosure, some companies mentioned by Erik in this interview, are positions held in his personal portfolio, and also may be site sponsors of The Hedgeless Horseman website at the time of this recording.   Click here to follow Erik's analysis over at The Hedgeless Horseman website

Former President John Mahama has officially cut the sod to begin Phase II of the Blekusu Coastal Protection Project. The ceremony took place at Agavedzi in the Ketu South constituency, where he was joined by local residents and traditional leaders.

SES has completed the acquisition of Intelsat. Planet Labs has announced a multi-year contract expansion with the Instituto Geográfico Agustín Codazzi (IGAC) in Colombia. Solestial has been selected by SpaceWERX for a Direct-to-Phase II contract in the amount of $1.2 million, and more. Remember to leave us a 5-star rating and review in your favorite podcast app. Be sure to follow T-Minus on LinkedIn and Instagram. T-Minus Guest Our guest today is Jacob Oakley,   Technical Director at SIXGEN and Space Lead for the DEFCON Aerospace Village.  You can connect with Jacob on LinkedIn, and learn more about the Aerospace Village on their website. Selected Reading SES Completes Acquisition of Intelsat, Creating Global Multi-Orbit Connectivity Powerhouse Planet Expands Multi-Year Contract with Instituto Geográfico Agustín Codazzi (IGAC), Providing Satellite Data and AI-Powered Analytics Feeds Across Colombia Solestial Awarded $1.2M by SpaceWERX for Space Solar Development SpaceX Plans Starship Program for In-Orbit Drug Research - Bloomberg ISS National Lab's Orbital Edge Accelerator Program Selects Six Startups NASA Sees Key Progress on Starlab Commercial Space Station Astronomers capture the birth of planets around a baby sun outside our solar system The handshake in orbit that made the International Space Station possible T-Minus Crew Survey Complete our annual audience survey before August 31. Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at space@n2k.com to request more info. Want to join us for an interview? Please send your pitch to space-editor@n2k.com and include your name, affiliation, and topic proposal. T-Minus is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc. Learn more about your ad choices. Visit megaphone.fm/adchoices

We weigh in on the recent DoJ Epstein memo and tape. Plus: Elon and Hitler. Hit the tip line: (646) 801-1129 | tips@trueanon.com Discover more episodes at podcast.trueanon.com

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 11, 2025. In this episode: Merck & Co's Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee's Phase II eczema win; and a look at India's wave of licensing. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-TJX4YBGD5JDSHGRUTLYHWO2JMU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

This is Part 5 of the Phantoms Main Camp Recap! On deck, we welcome back Friend of the Show, Assistant GM Robbie Murden, and for the 1st time, we welcome Assistant GM and Director of European Scouting Adam Jonak! Robbie and Adam take us through some of this year's Phase II picks. Check it out!Send us a textMerch Store Official WebsiteFacebook This recording is the sole view of the members of the Dump & Chase Podcast. This is a non-commercial fan production. We are not affiliated with or compensated by the Youngstown Phantoms, the United States Hockey League, or any league, club, or team. © 2025 Dump & Chase Podcast. All Rights Reserved

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Beckley's psychedelic nasal spray, BPL-003, has successfully cleared Phase II trials for treatment-resistant depression, showing robust efficacy data. Analysts predict the asset could reach peak market sales of $1 billion. This paves the way for late-stage development and a proposed merger with atai life sciences. In other news, M&A activity saw a significant increase in June, with big pharmas like Eli Lilly, Sanofi, and Novartis making multiple deals. The FDA's decision to remove risk evaluation and mitigation strategies from approved CAR T cancer therapies has been well-received by the cell and gene therapy community. Additionally, Argenx has made a $1.5 billion acquisition of Unum Therapeutics' macrocyclic peptides, aimed at "undruggable" targets. Moderna, Merck, UroGen, and other companies received regulatory nods for various treatments in June. Evotec is hosting a webinar on preserving quality in the pharma industry amidst financial challenges on July 16. Job opportunities in the industry include positions at Biomarin Pharmaceutical Inc., Regeneron Pharmaceuticals, and AbbVie.

The U.S. Supreme Court closed out its session before breaking for summer on Friday, ruling that decisions around coverage of HIV PrEP drugs should be left up to the U.S. Preventive Services Task Force. The ruling thwarted a lawsuit brought by a group of insurance providers who challenged the Affordable Care Act's requirement that they cover preventive medicines, such as HIV drugs, recommended by the task force. The high court also determined that members of this task force can be removed at will by HHS Secretary Robert F. Kennedy Jr.Speaking of HHS committees from which members have been removed at will by Kennedy, the CDC's revamped Advisory Committee on Immunization Practices convened last week for its first meeting since the roster overhaul, where a vote on Merck's recently approved RSV-targeting monoclonal antibody Enflonsia and a discussion around the inclusion of preservative thimerosal in influenza vaccines was on the docket, but an expected vote on Moderna's mRNA-based RSV shot mRESVIA was not.Also dominating the headlines on Friday was the FDA's decision to remove the Risk Evaluation and Mitigation Strategies (REMS) program from the six approved CAR T therapies it was applied to. Analysts and patient groups lauded the move, which is expected to potentially double access to these life-saving therapies, saying it reflects “thoughtful consideration of real-world evidence” and “regulatory trust.”Willliam Blair noted that it could be a “positive signal” to companies developing CAR T therapies for autoimmune diseases, which now includes AbbVie. In an all-cash buyout on Monday, the Illinois-based pharma dropped $1.2 billion for Capstan Therapeutics and its in vivo edited CAR T therapy for B cell–mediated autoimmune diseases. M&A has been on an uptick of late, and private equity companies—such as those that snapped up bluebird bio—are also getting in on the game.Finally, after Lykos Therapeutics' high profile failure last summer, the psychedelics space is heating up once again. While a Phase III readout of Compass Pathways' psilocybin drug last week in treatment-resistant depression received a muted reaction from investors, the response to a Phase II readout for Beckley Psytech and atai Life Sciences' intranasal psychedelic was more positive.

Send us a textEpisode Description:In this episode, we sit down with pianist, singer, and producer Johanna Chukaree — better known as D Piano Girl — for an honest and uplifting conversation about creativity, healing, and purpose.Johanna shares her journey from early classical training and national music festival wins to a corporate career in engineering and HR — before finally stepping fully into her artistry. We get into the story behind her viral Savannah Grass cover, the emotional layers of her new single Forever, and how she blended Bollywood rhythms, Hindi lyrics, and Trinbagonian spirit to produce a deeply personal anthem.We talk about her process, her voice, and how music became a way to process life, raise her vibration, and reconnect with joy. From working out Phase II Pan Groove intros as a child in Woodbrook to making original music heard on major stations, Johanna opens up about learning to believe in herself — and how that belief shapes everything around her.

The aftermath of the attack on Callista's club leaves a bullet-ridden Lincoln scrambling to heal in time for Phase II of Dante's plan. Icepick is about to hear from a very unhappy employer. And through it all, the ticking time bomb that is Lincoln's family finally goes “boom.” Created by Scott Sigler and Rob Otto Written and performed by Scott Sigler Production Assistance by Allie Press Copyright 2025 by Empty Set Entertainment  Theme music is the song “They're Watching Me” by SUPERWEAPON. Family drama? Patch things up with a family website. Save 99% on a new dot-com with the GoDaddy Promo Code CJCFOSSIG3. Learn more about your ad choices. Visit megaphone.fm/adchoices

Topics covered in this episode: * Free-threaded Python no longer “experimental” as of Python 3.14* typed-ffmpeg pyleak * Optimizing Test Execution: Running live_server Tests Last with pytest* Extras Joke Watch on YouTube About the show Sponsored by PropelAuth: pythonbytes.fm/propelauth66 Connect with the hosts Michael: @mkennedy@fosstodon.org / @mkennedy.codes (bsky) Brian: @brianokken@fosstodon.org / @brianokken.bsky.social Show: @pythonbytes@fosstodon.org / @pythonbytes.fm (bsky) Join us on YouTube at pythonbytes.fm/live to be part of the audience. Usually Monday at 10am PT. Older video versions available there too. Finally, if you want an artisanal, hand-crafted digest of every week of the show notes in email form? Add your name and email to our friends of the show list, we'll never share it. Brian #1: Free-threaded Python no longer “experimental” as of Python 3.14 “PEP 779 ("Criteria for supported status for free-threaded Python") has been accepted, which means free-threaded Python is now a supported build!” - Hugo van Kemenade PEP 779 – Criteria for supported status for free-threaded Python As noted in the discussion of PEP 779, “The Steering Council (SC) approves PEP 779, with the effect of removing the “experimental” tag from the free-threaded build of Python 3.14.” We are in Phase II then. “We are confident that the project is on the right path, and we appreciate the continued dedication from everyone working to make free-threading ready for broader adoption across the Python community.” “Keep in mind that any decision to transition to Phase III, with free-threading as the default or sole build of Python is still undecided, and dependent on many factors both within CPython itself and the community. We leave that decision for the future.” How long will all this take? According to Thomas Wouters, a few years, at least: “In other words: it'll be a few years at least. It can't happen before 3.16 (because we won't have Stable ABI support until 15) and may well take longer.” Michael #2: typed-ffmpeg typed-ffmpeg offers a modern, Pythonic interface to FFmpeg, providing extensive support for complex filters with detailed typing and documentation. Inspired by ffmpeg-python, this package enhances functionality by addressing common limitations, such as lack of IDE integration and comprehensive typing, while also introducing new features like JSON serialization of filter graphs and automatic FFmpeg validation. Features : Zero Dependencies: Built purely with the Python standard library, ensuring maximum compatibility and security. User-Friendly: Simplifies the construction of filter graphs with an intuitive Pythonic interface. Comprehensive FFmpeg Filter Support: Out-of-the-box support for most FFmpeg filters, with IDE auto-completion. Integrated Documentation: In-line docstrings provide immediate reference for filter usage, reducing the need to consult external documentation. Robust Typing: Offers static and dynamic type checking, enhancing code reliability and development experience. Filter Graph Serialization: Enables saving and reloading of filter graphs in JSON format for ease of use and repeatability. Graph Visualization: Leverages graphviz for visual representation, aiding in understanding and debugging. Validation and Auto-correction: Assists in identifying and fixing errors within filter graphs. Input and Output Options Support: Provide a more comprehensive interface for input and output options, including support for additional codecs and formats. Partial Evaluation: Enhance the flexibility of filter graphs by enabling partial evaluation, allowing for modular construction and reuse. Media File Analysis: Built-in support for analyzing media files using FFmpeg's ffprobe utility, providing detailed metadata extraction with both dictionary and dataclass interfaces. Michael #3: pyleak Detect leaked asyncio tasks, threads, and event loop blocking with stack trace in Python. Inspired by goleak. Use as context managers or function dectorators When using no_task_leaks, you get detailed stack trace information showing exactly where leaked tasks are executing and where they were created. Even has great examples and a pytest plugin. Brian #4: Optimizing Test Execution: Running live_server Tests Last with pytest Tim Kamanin “When working with Django applications, it's common to have a mix of fast unit tests and slower end-to-end (E2E) tests that use pytest's live_server fixture and browser automation tools like Playwright or Selenium. ” Tim is running E2E tests last for Faster feedback from quick tests To not tie up resources early in the test suite. He did this with custom “e2e” marker Implementing a pytest_collection_modifyitems hook function to look for tests using the live_server fixture, and for them automatically add the e2e marker to those tests move those tests to the end The reason for the marker is to be able to Just run e2e tests with -m e2e Avoid running them sometimes with -m "not e2e" Cool small writeup. The technique works for any system that has some tests that are slower or resource bound based on a particular fixture or set of fixtures. Extras Brian: Is Free-Threading Our Only Option? - Interesting discussion started by Eric Snow and recommended by John Hagen Free-threaded Python on GitHub Actions - How to add FT tests to your projects, by Hugo van Kemenade Michael: New course! LLM Building Blocks in Python Talk Python Deep Dives Complete: 600K Words of Talk Python Insights .folders on Linux Write up on XDG for Python devs. They keep pulling me back - ChatGPT Pro with o3-pro Python Bytes is the #1 Python news podcast and #17 of all tech news podcasts. Python 3.13.4, 3.12.11, 3.11.13, 3.10.18 and 3.9.23 are now available Python 3.13.5 is now available! Joke: Naming is hard

Zach catches up on the three newest series to be released in the DC Absolute Universe!On the docket:Absolute Martian Manhunter #1-3 (DC Comics)Written by Deniz CampArt by Javier RodriguezLetters by Hassan Otsmane-ElhaouAbsolute Flash #1-3 (DC Comics)Written by Jeff LemireArt by Nick RoblesColors by Adriano LucasLetters by Tom NapolitanoAbsolute Green Lantern #1-2 (DC Comics)Written by Al EwingArt by Jahnoy LindsayLetters by Lucas Gattoni---------------------------------------------------Check out Dreampass and all their killer tracks on Spotify!---------------------------------------------------Join the Patreon to help us keep the lights on, and internet connected! https://www.patreon.com/tctwl---------------------------------------------------Listen to my other podcast!TFD: NerdcastAnd I am also part of the team over at...I Read Comic Books!---------------------------------------------------Want to try out all the sweet gigs over on Fiverr.com? Click on the link below and sign up!https://go.fiverr.com/visit/?bta=323533&brand=fiverrcpa---------------------------------------------------Follow on Instagram!The Comics That We LoveFollow on Tiktok!The Comics that We LoveFollow on Bluesky!comicsthatwelove.bsky.social

Let us know if there's a topic you'd like us to cover! Welcome back to Green Industry Perspectives! In this episode, Jay Worth welcomes Marie Ambusk to the show!A bad experience with a landscaper set Marie on a nearly two-decade journey to make things right. When the street trees in her neighborhood failed after less than 20 years, she asked the landscape company replacing them what happened. The answer, "You get what you get, lady," made her blood boil. Since then, she's not only become a Master Gardener. She's developed a way to determine if trees are going to fail. Those street trees had root collar disorder. Once she realized the problem lay in the containers and growing phase, she developed a way to inspect the root systems of containerized trees. Using ground-penetrating radar (GPR), AI, and machine-learning, she's been able to map and grade the root systems of container trees to predict failure with a stunning degree of accuracy. Phase II of her project will focus on using the same GPR technology to map defects in planted trees, saving many hours of labor in excavation to look for problems. In this episode, Marie shares why customer satisfaction, employee opportunities, and company growth and profit make the difference to your success in the Green Industry. For her, they all boil down to one core issue: establishing trust. ---Check Out the SingleOps Events Page!Check Out the LMN Events Page!---Visit the Trees ROI WebsiteConnect with Marie on LinkedInVisit the Trees ROI Facebook PageVisit the TREEage Vermont Facebook Page

Dutch biotech Merus' EGFR x LGR5 bispecific antibody has caught investors' attention in the run-up to ASCO as a new approach to block EGFR signaling. On the latest BioCentury This Week podcast, BioCentury's analysts discuss Phase II data from Merus for petosemtamab as they preview the American Society of Clinical Oncology's upcoming annual meeting. The analysts also assess a setback in a gene therapy trial for Rocket Pharmaceuticals, renewed interest in cancer target EpCAM, and a flurry of biopharma activity on the Hong Kong stock exchange. Finally, the team previews BioCentury's second annual Grand Rounds R&D meeting, which takes place next week in Chicago. This episode was sponsored by Jeito Capital.View full story: https://www.biocentury.com/article/656038#biotech #biopharma #pharma #lifescience #RandD #DrugDevelopment00:01 - Sponsor Message: Jeito Capital24:52 - HK IPOs07:12 - ASCO16:37 - EpCAM20:16 - RocketTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Robby Stanley and Paul Kuharsky, who is in for Rexrode the rest of the week, are talking all things Titans and NFL today.  What are some NFL headlines that are standing out early on?  The Titans are in Phase II of OTAs.  What do we think about how Callahan said the team is trying to address the mistakes from last season?  How much more sophisticated could the offense be this upcoming season?  Callahan gave an update on L'Jarius Sneed and his recovery from injury.

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract  Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications

Phase II of the offseason program is underway in Tempe as the Arizona Cardinals rookies join the veterans for work. Craig Grialou, Paul Calvisi and former Cardinals QB Drew Stanton talk about building in the offseason, rookie CB Will Johnson's fit in Nick Rallis' defense, what kind of role we'll see from OLB Jordan Burch and if a push to start is realistic for sixth-round guard Hayden Conner out of Texas.See omnystudio.com/listener for privacy information.

Jamie is a 62-year-old female who is referred to outpatient cardiac rehabilitation 3 weeks after a myocardial infarction. She reports feeling fatigued with moderate exertion but denies chest pain. Her resting vitals are HR 80 bpm, BP 128/82 mmHg, and SpO₂ 98%. She completed Phase I rehabilitation without complications and is eager to begin exercising to improve her endurance. Which activity is MOST appropriate to initiate during Phase II of cardiac rehabilitation?A) Jogging on a treadmill at 70% maximum heart ratB) Cycling on a stationary bike at 3-5 METsC) Strength training at 50% of 1-rep maxD) Stretching and light walking onlyDOWNLOAD THIS EPISODES CHEATSHEET:www.nptecheatsheet.com/cardiac-rehab1

It's public space night, and the wide ranging group discussion ensues. Grant joins Tore for the evening. Bringing people along slowly takes a strategy. Credible information can be fed to soft prime the world. It's disclosure, but a gentle one. Thru whistle blowers works great. We are actually in Phase II. There's more than one Arc Of The Covenant. Science created one version. Huh? Planet X could raise gravitational havoc. Why would NASA be hinting? Poles have flipped before, but we didn't depend on tech back then. Another Y2K? Pyramids exist all over the world. Advanced ancient tech is a good bait subject. Tesla terrorists could be planted. Bergrum and the contract tracing app. What did Jesus study in the unknown years. Was alchemy on the list? Religion as a whip has been very effective. When two or more gather, that's a church. They hijacked all religions, not just Christianity. How important is your faith to you? Dialing God's number outside the space. Focusing on life's purpose, which is service to others. And, it's reciprocal. The essence of the Koran is actually love. The big question remains, is free will there too? Going to bliss without Netflix. The pyramids might be at the epicenter of what's to come. Love yourself and God, then the rest will come naturally.